COMMUNIQUÉS West-GlobeNewswire

Record-Breaking Pro Skateboarder Danny Way Becomes Safety Shot Brand Ambassador
15/02/2024
JUPITER, FL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) is pleased to announce that Danny Way, an American professional skateboarder and business person, has joined Safety Shot as a brand [...]
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
15/02/2024
The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular (IM) injection. [...]
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
15/02/2024
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, [...]
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
15/02/2024
SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of [...]
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
15/02/2024
Strategic promotion underscores commitment to commercial growth across Ocular portfolio BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on [...]
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
15/02/2024
KNOXVILLE, TN, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at 3 p.m. EST on Thursday, [...]
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
15/02/2024
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of [...]
10 Barrel Brewing Co. Announces Official Beer Sponsorship of the Natural Selection Tour
15/02/2024
10 Barrel’s Pub Beer to Elevate the Après Snowboarding Scene BEND, Ore., Feb. 15, 2024 (GLOBE NEWSWIRE) -- 10 Barrel Brewing Co. (“10 Barrel Brewing Co.” or “10 Barrel”), a trailblazer in the craft brewing industry and [...]
LifeMD to Participate in Upcoming Investor Conferences and Webinar
15/02/2024
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced that management will be participating in three upcoming investor conferences and a [...]
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
15/02/2024
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical [...]
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
15/02/2024
LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and [...]
Extendicare Announces February 2024 Dividend of C$0.04 per Share
15/02/2024
MARKHAM, Ontario, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]
Vaccinex, Inc. Announces Reverse Stock Split
15/02/2024
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the [...]
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
15/02/2024
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today [...]
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
15/02/2024
Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS High-dose frexalimab significantly reduced disease activity, demonstrating 89% reduction in new brain lesions Phase 3 [...]
Communiqué de presse : Des données de phase II publiées dans le NEJM illustrent le fort potentiel d’efficacité du frexalimab dans le traitement de la sclérose en plaques récurrente-rémittente
15/02/2024
Des données de phase II publiées dans le NEJM illustrent le fort potentiel d’efficacité du frexalimab dans le traitement de la sclérose en plaques récurrente-rémittente Le frexalimab à dose élevée a permis de réduire [...]
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
15/02/2024
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a [...]
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15/02/2024
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for [...]
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
15/02/2024
Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the reach of gene [...]

Pages